4//SEC Filing
SUN ANTHONY Y 4
Accession 0001725160-22-000031
CIK 0001725160other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 9:08 PM ET
Size
15.0 KB
Accession
0001725160-22-000031
Insider Transaction Report
Form 4
SUN ANTHONY Y
DirectorPresident & CEO
Transactions
- Award
Common Stock
2022-02-10+50,431→ 1,222,206 total - Sale
Common Stock
2022-02-14$50.16/sh−4,208$211,091→ 1,217,998 total - Sale
Common Stock
2022-02-14$50.75/sh−525$26,642→ 1,217,473 total - Award
Stock Option (Right to Buy)
2022-02-10+118,319→ 118,319 totalExercise: $52.61Exp: 2032-02-09→ Common Stock (118,319 underlying)
Holdings
- 213,600(indirect: By Trust)
Common Stock
- 103,650(indirect: By Spouse)
Common Stock
- 974,302(indirect: By LLC)
Common Stock
- 125,000(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
- [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
- [F6]Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
- [F7]The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001377952
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 9:08 PM ET
- Size
- 15.0 KB